Microarray Synthesis and Assembly of Gene-Length Polynucleotides

ABSTRACT

There is disclosed a process for in vitro synthesis and assembly of long, gene-length polynucleotides based upon assembly of multiple shorter oligonucleotides synthesized in situ on a microarray platform. Specifically, there is disclosed a process for in situ synthesis of oligonucleotide fragments on a solid phase microarray platform and subsequent, “on device” assembly of larger polynucleotides composed of a plurality of shorter oligonucleotide fragments.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.13/250,207, filed on Sep. 30, 2011, which is a continuation of U.S.patent application Ser. No. 12/488,662, filed on Jun. 22, 2009, now U.S.Pat. No. 8,058,004, which is a continuation of U.S. patent applicationSer. No. 10/243,367, filed on Sep. 12, 2002, now U.S. Pat. No.7,563,600, the content of all of which is incorporated herein byreference in their entirety.

TECHNICAL FIELD OF THE INVENTION

The present invention provides a process for in vitro synthesis andassembly of long, gene-length polynucleotides based upon assembly ofmultiple shorter oligonucleotides synthesized in situ on a microarrayplatform. Specifically, the present invention provides a process for insitu synthesis of oligonucleotide sequence fragments on a solid phasemicroarray platform and subsequent, “on chip” assembly of largerpolynucleotides composed of a plurality of smaller oligonucleotidesequence fragments.

BACKGROUND OF THE INVENTION

In the world of microarrays, biological molecules (e.g.,oligonucleotides, polypeptides and the like) are placed onto surfaces atdefined locations for potential binding with target samples ofnucleotides or receptors. Microarrays are miniaturized arrays ofbiomolecules available or being developed on a variety of platforms.Much of the initial focus for these microarrays have been in genomicswith an emphasis of single nucleotide polymorphisms (SNPs) and genomicDNA detection/validation, functional genomics and proteomics (Wilgenbusand Lichter, J. Mol. Med. 77:761, 1999; Ashfari et al., Cancer Res.59:4759, 1999; Kurian et al., J. Pathol. 187:267, 1999; Hacia, NatureGenetics 21 suppl.: 42, 1999; Hacia et al., Mol. Psychiatry 3:483, 1998;and Johnson, Curr. Biol. 26:R171, 1998).

There are, in general, three categories of microarrays (also called“biochips” and “DNA Arrays” and “Gene Chips” but this descriptive namehas been attempted to be a trademark) having oligonucleotide content.Most often, the oligonucleotide microarrays have a solid surface,usually silicon-based and most often a glass microscopic slide.Oligonucleotide microarrays are often made by different techniques,including (1) “spotting” by depositing single nucleotides for in situsynthesis or completed oligonucleotides by physical means (ink jetprinting and the like), (2) photolithographic techniques for in situoligonucleotide synthesis (see, for example, Fodor U.S. Pat. No. '934and the additional patents that claim priority from this prioritydocument, (3) electrochemical in situ synthesis based upon pH basedremoval of blocking chemical functional groups (see, for example,Montgomery U.S. Pat. No. 6,092,302 the disclosure of which isincorporated by reference herein and Southern U.S. Pat. No. 5,667,667),and (4) electric field attraction/repulsion of fully-formedoligonucleotides (see, for example, Hollis et al., U.S. Pat. No.5,653,939 and its duplicate Heller U.S. Pat. No. 5,929,208). Only thefirst three basic techniques can form oligonucleotides in situ e.g.,building each oligonucleotide, nucleotide-by-nucleotide, on themicroarray surface without placing or attracting fully formedoligonucleotides.

With regard to placing fully formed oligonucleotides at specificlocations, various micro-spotting techniques using computer-controlledplotters or even ink-jet printers have been developed to spotoligonucleotides at defined locations. One technique loads glass fibershaving multiple capillaries drilled through them with differentoligonucleotides loaded into each capillary tube. Microarray chips,often simply glass microscope slides, are then stamped out much like arubber stamp on each sheet of paper of glass slide. It is also possibleto use “spotting” techniques to build oligonucleotides in situ.Essentially, this involves “spotting” relevant single nucleotides at theexact location or region on a slide (preferably a glass slide) where aparticular sequence of oligonucleotide is to be built. Therefore,irrespective of whether or not fully formed oligonucleotides or singlenucleotides are added for in situ synthesis, spotting techniques involvethe precise placement of materials at specific sites or regions usingautomated techniques.

Another technique involves a photolithography process involvingphotomasks to build oligonucleotides in situ, base-by-base, by providinga series of precise photomasks coordinated with single nucleotide baseshaving light-cleavable blocking groups. This technique is described inFodor et al., U.S. Pat. No. 5,445,934 and its various progeny patents.Essentially, this technique provides for “solid-phase chemistry,photolabile protecting groups, and photolithography . . . to achievelight-directed spatially-addressable parallel chemical synthesis.”

The electrochemistry platform (Montgomery U.S. Pat. No. 6,092,302, thedisclosure of which is incorporated by reference herein) provides amicroarray based upon a semiconductor chip platform having a pluralityof microelectrodes. This chip design uses Complimentary Metal OxideSemiconductor (CMOS) technology to create high-density arrays ofmicroelectrodes with parallel addressing for selecting and controllingindividual microelectrodes within the array. The electrodes turned onwith current flow generate electrochemical reagents (particularly acidicprotons) to alter the pH in a small “virtual flask” region or volumeadjacent to the electrode. The microarray is coated with a porous matrixfor a reaction layer material. Thickness and porosity of the material iscarefully controlled and biomolecules are synthesized within volumes ofthe porous matrix whose pH has been altered through controlled diffusionof protons generated electrochemically and whose diffusion is limited bydiffusion coefficients and the buffering capacities of solutions.However, in order to function properly, the microarray biochips usingelectrochemistry means for in situ synthesis has to alternate anodes andcathodes in the array in order to generated needed protons (acids) atthe anodes so that the protons and other acidic electrochemicallygenerated acidic reagents will cause an acid pH shift and remove ablocking group from a growing oligomer.

Gene Assembly

The preparation of arbitrary polynucleotide sequences is useful in a“postgenomic” era because it provides any desirable gene oligonucleotideor its fragment, or even whole genome material of plasmids, phages andviruses. Such polynucleotides are long, such as in excess of 1000 basesin length. In vitro synthesis of oligonucleotides (given even the bestyield conditions of phosphoramidite chemistry) would not be feasiblebecause each base addition reaction is less than 100% yield. Therefore,researchers desiring to obtain long polynucleotides of gene length orlonger had to turn to nature or gene isolation techniques to obtainpolynucleotides of such length. For the purposes of this patentapplication, the term “polynucleotide” shall be used to refer to nucleicacids (either single stranded or double stranded) that are sufficientlylong so as to be practically not feasible to make in vitro throughsingle base addition. In view of the exponential drop-off in yields fromnucleic acid synthesis chemistries, such as phosphoramidite chemistry,such polynucleotides generally have greater than 100 bases and oftengreater than 200 bases in length. It should be noted that manycommercially useful gene cDNA's often have lengths in excess of 1000bases.

Moreover, the term “oligonucleotides” or shorter term “oligos” shall beused to refer to shorter length single stranded or double strandednucleic acids capable of in vitro synthesis and generally shorter than150 bases in length. While it is theoretically possible to synthesizepolynucleotides through single base addition, the yield losses make it apractical impossibility beyond 150 bases and certainly longer than 250bases.

However, knowledge of the precise structure of the genetic material isoften not sufficient to obtain this material from natural sources.Mature cDNA, which is a copy of an mRNA molecule, can be obtained if thestarting material contains the desired mRNA. However, it is not alwaysknown if the particular mRNA is present in a sample or the amount of themRNA might be too low to obtain the corresponding cDNA withoutsignificant difficulties. Also, different levels of homology or splicevariants may interfere with obtaining one particular species of mRNA. Onthe other hand many genomic materials might be not appropriate toprepare mature gene (cDNA) due to exon-intron structure of genes in manydifferent genomes.

In addition, there is a need in the art for polynucleotides not existingin nature to improve genomic research performance. In general, theability to obtain a polynucleotide of any desired sequence just knowingthe primary structure, for a reasonable price, in a short period oftime, will significantly move forward several fields of biomedicalresearch and clinical practice.

Assembly of long arbitrary polynucleotides from oligonucleotidessynthesized by organic synthesis and individually purified has otherproblems. The assembly can be performed using PCR or ligation methods.The synthesis and purification of many different oligonucleotides byconventional methods (even using multi-channel synthesizers) arelaborious and expensive procedures. The current price of assembledpolynucleotide on the market is about $12-25 per base pair, which can beconsiderable for assembling larger polynucleotides. Very often theamount of conventionally synthesized oligonucleotides would beexcessive. This also contributes to the cost of the final product.

Therefore, there is a need in the art to provide cost-effectivepolynucleotides by procedures that are not as cumbersome andlabor-intensive as present methods to be able to provide polynucleotidesat costs below $1 per base or 1-20 times less than current methods. Thepresent invention was made to address this need.

SUMMARY OF THE INVENTION

The present invention provides a process for the assembly ofoligonucleotides synthesized on microarrays into a polynucleotidesequence. The desired target polynucleotide sequence is dissected intopieces of overlapping oligonucleotides. In the first embodiment theseoligonucleotides are synthesized in situ, in parallel on a microarraychip in a non-cleavable form. A primer extension process assembles thetarget polynucleotides. The primer extension process uses startingprimers that are specific for the appropriate sequences. The last stepis PCR amplification of the final polynucleotide product. Preferably,the polynucleotide product is a cDNA suitable for transcription purposesand further comprising a promoter sequence for transcription.

The present invention provides a process for assembling a polynucleotidefrom a plurality of oligonucleotides comprising:

(a) synthesizing or spotting a plurality of oligonucleotide sequences ona microarray device or bead device having a solid or porous surface,wherein a first oligonucleotide is oligo 1 and a second oligonucleotideis oligo 2 and so on, wherein the plurality of oligonucleotide sequencesare attached to the solid or porous surface, and wherein the firstoligonucleotide sequence has an overlapping sequence region of fromabout 10 to about 50 bases that is the same or substantially the same asa region of a second oligonucleotide sequence, and wherein the secondoligonucleotide sequence has an overlapping region with a thirdoligonucleotide sequence and so on;

(b) forming complementary oligo 1 by extending primer 1, wherein primer1 is complementary to oligo 1;

(c) disassociating complementary oligo 1 from oligo 1 and annealingcomplementary oligo 1 to both oligo 1 and to the overlapping region ofoligo 2, wherein the annealing of complementary oligo 1 to oligo 2serves as a primer for extension for forming complementary oligo 1+2;

(d) repeating the primer extension cycles of step (c) until afull-length polynucleotide is produced; and

(e) amplifying the assembled complementary full length polynucleotide toproduce a full length polynucleotide in desired quantities.

Preferably, the solid or porous surface is in the form of a microarraydevice. Most preferably, the microarray device is a semiconductor devicehaving a plurality of electrodes for synthesizing oligonucleotides insitu using electrochemical means to couple and decouple nucleotidebases. Preferably, the primer extension reaction is conducted through asequential process of melting, annealing and then extension. Mostpreferably, the primer extension reaction is conducted in a PCRamplification device using the microarray having the plurality ofoligonucleotides bound thereto.

The present invention further provides a process for assembling apolynucleotide from a plurality of oligonucleotides comprising:

(a) synthesizing in situ or spotting a plurality of oligonucleotidesequences on a microarray device or bead device each having a solid orporous surface, wherein the plurality of oligonucleotide sequences areattached to the solid or porous surface, and wherein eacholigonucleotide sequence has an overlapping region corresponding to anext oligonucleotide sequence within the sequence and further comprisestwo flanking sequences, one at the 3′ end and the other at the 5′ end ofeach oligonucleotide, wherein each flanking sequence is from about 7 toabout 50 bases and comprising a primer region and a sequence segmenthaving a restriction enzyme cleavable site;

(b) amplifying each oligonucleotide using the primer regions of theflanking sequence to form double stranded (ds) oligonucleotides;

(c) cleaving the oligonucleotide sequences at the restriction enzymecleavable site; and

(d) assembling the cleaved oligonucleotide sequences through theoverlapping regions to form a full length polynucleotide.

Preferably, the flanking sequence is from about 10 to about 20 bases inlength. Preferably, the restriction enzyme cleavable site is a class IIendonuclease restriction site sequence capable of being cleaved by itscorresponding class II restriction endonuclease enzyme. Most preferably,the restriction endonuclease class II site corresponds to restrictionsites for a restriction endonuclease class II enzyme selected from thegroup consisting of Mly I, BspM I, Bae I, BsaX I, Bsr I, Bmr I, Btr I,Bts I, Fok I, and combinations thereof. Preferably, the flankingsequence further comprises a binding moiety used to purify cleavedoligonucleotides from flanking sequences. Preferably, the processfurther comprises the step of labeling the flanking sequence during theamplification step (b) using primer sequences labeled with bindingmoieties. Most preferably, a binding moiety is a small molecule able tobe captured, such as biotin captured by avidin or streptavidin, orfluorescein able to be captured by an anti-fluorescein antibody.

The present invention further provides a process for assembling apolynucleotide from a plurality of oligonucleotides comprising:

(a) synthesizing in situ or spotting a plurality of oligonucleotidesequences on a microarray device or bead device each having a solid orporous surface, wherein the plurality of oligonucleotide sequences areattached to the solid or porous surface, and wherein eacholigonucleotide sequence has an overlapping region corresponding to anext oligonucleotide sequence within the sequence, and further comprisesa sequence segment having a cleavable linker moiety;

(b) cleaving the oligonucleotide sequences at the cleavable linker siteto cleave each oligonucleotide complex from the microarray or bead solidsurface to form a soluble mixture of oligonucleotides, each having anoverlapping sequence; and

(c) assembling the oligonucleotide sequences through the overlappingregions to form a full length polynucleotide.

Preferably, the cleavable linker is a chemical composition having asuccinate moiety bound to a nucleotide moiety such that cleavageproduces a 3′hydroxy nucleotide. Most preferably, the cleavable linkeris selected from the group consisting of5′-dimethoxytrityl-thymidine-3′succinate,4-N-benzoyl-5′-dimethoxytrityl-deoxycytidine-3′-succinate,1-N-benzoyl-5′-dimethoxytrityl-deoxyadenosine-3′-succinate,2-N-isobutyryl-5′-dimethoxytrityl-deoxyguanosone-3′-succinate, andcombinations thereof.

The present invention further provides a process for assembling apolynucleotide from a plurality of oligonucleotides comprising:

(a) synthesizing in situ or spotting a plurality of oligonucleotidesequences on a microarray device or bead device each having a solid orporous surface, wherein the plurality of oligonucleotide sequences areattached to the solid or porous surface, and wherein eacholigonucleotide sequence has a flanking region at an end attached to thesolid or porous surface, and a specific region designed by dissectingthe polynucleotide sequence into a plurality of overlappingoligonucleotides, wherein a first overlapping sequence on a firstoligonucleotide corresponds to a second overlapping sequence of a secondoligonucleotide, and wherein the flanking sequence comprises a sequencesegment having a restriction endonuclease (RE) recognition sequencecapable of being cleaved by a corresponding RE enzyme;

(b) hybridizing an oligonucleotide sequence complementary to theflanking region to form a double stranded sequence capable ofinteracting with the corresponding RE enzyme;

(c) digesting the plurality of oligonucleotides to cleave them from themicroarray device or beads into a solution; and

(d) assembling the oligonucleotide mixture through the overlappingregions to form a full length polynucleotide.

Preferably, the flanking sequence is from about 10 to about 20 bases inlength. Preferably, the restriction enzyme cleavable site is a class IIendonuclease restriction site sequence capable of being cleaved by itscorresponding class II restriction endonuclease enzyme. Most preferably,the restriction endonuclease class II site corresponds to restrictionsites for a restriction endonuclease class II enzyme selected from thegroup consisting of Mly I, BspM I, Bae I, BsaX I, Bsr I, Bmr I, Btr I,Bts I, Fok I, and combinations thereof. Preferably, the process furthercomprises a final step of amplifying the polynucleotide sequence usingprimers located at both ends of the polynucleotide.

The present invention further provides a process for creating a mixtureof oligonucleotide sequences in solution comprising:

(a) synthesizing in situ or spotting a plurality of oligonucleotidesequences on a microarray device or bead device each having a solid orporous surface, wherein the plurality of oligonucleotide sequences areattached to the solid or porous surface, and wherein eacholigonucleotide sequence further comprises two flanking sequences, oneat the 3′ end and the other at the 5′ end of each oligonucleotide,wherein each flanking sequence is from about 7 to about 50 bases andcomprising a primer region and a sequence segment having a restrictionenzyme cleavable site;

(b) amplifying each oligonucleotide using the primer regions of theflanking sequence to form a double stranded (ds) oligonucleotides; and

(c) cleaving the double stranded oligonucleotide sequences at therestriction enzyme cleavable site.

Preferably, the flanking sequence is from about 10 to about 20 bases inlength. Preferably, the restriction enzyme cleavable site is a class IIendonuclease restriction site sequence capable of being cleaved by itscorresponding class II restriction endonuclease enzyme. Most preferably,the restriction endonuclease class II site corresponds to restrictionsites for a restriction endonuclease class II enzyme selected from thegroup consisting of Mly I, BspM I, Bae I, BsaX I, Bsr I, Bmr I, Btr I,Bts I, Fok I, and combinations thereof. Preferably, the flankingsequence further comprises a binding moiety used to purify cleavedoligonucleotides from flanking sequences. Preferably, the processfurther comprises the step of labeling the flanking sequence during theamplification step (b) using primer sequences labeled with bindingmoieties. Most preferably, a binding moiety is a small molecule able tobe captured, such as biotin captured by avidin or streptavidin, orfluorescein able to be captured by an anti-fluorescein antibody.

The present invention further provides a process for creating a mixtureof oligonucleotide sequences in solution comprising:

(a) synthesizing in situ or spotting a plurality of oligonucleotidesequences on a microarray device or bead device each having a solid orporous surface, wherein the plurality of oligonucleotide sequences areattached to the solid or porous surface, and wherein eacholigonucleotide sequence has a sequence segment having a cleavablelinker moiety;

(b) cleaving the oligonucleotide sequences at the cleavable linker siteto cleave each oligonucleotide sequence from the microarray or beadsolid surface to form a soluble mixture of oligonucleotides.

Preferably, the cleavable linker is a chemical composition having asuccinate moiety bound to a nucleotide moiety such that cleavageproduces a 3′hydroxy nucleotide. Most preferably, the cleavable linkeris selected from the group consisting of5′-dimethoxytrityl-thymidine-3′succinate,4-N-benzoyl-5′-dimethoxytrityl-deoxycytidine-3′-succinate,1-N-benzoyl-5′-dimethoxytrityl-deoxyadenosine-3′-succinate,2-N-isobutyryl-5′-dimethoxytrityl-deoxyguanosone-3′-succinate, andcombinations thereof.

The present invention further provides a process for creating a mixtureof oligonucleotide sequences in solution comprising:

(a) synthesizing in situ or spotting a plurality of oligonucleotidesequences on a microarray device or bead device each having a solid orporous surface, wherein the plurality of oligonucleotide sequences areattached to the solid or porous surface, and wherein eacholigonucleotide sequence has a flanking region at an end attached to thesolid or porous surface, and a specific region, wherein the flankingsequence comprises a sequence segment having a restriction endonuclease(RE) recognition sequence capable of being cleaved by a corresponding REenzyme;

(b) hybridizing an oligonucleotide sequence complementary to theflanking region to form a double stranded sequence capable ofinteracting with the corresponding RE enzyme;

(c) digesting the plurality of oligonucleotides to cleave them from themicroarray device or beads into a solution.

Preferably, the flanking sequence is from about 10 to about 20 bases inlength. Preferably, the restriction enzyme cleavable site is a class IIendonuclease restriction site sequence capable of being cleaved by itscorresponding class II restriction endonuclease enzyme. Most preferably,the restriction endonuclease class II site corresponds to restrictionsites for a restriction endonuclease class II enzyme selected from thegroup consisting of Mly I, BspM I, Bae I, BsaX I, Bsr I, Bmr I, Btr I,Bts I, Fok I, and combinations thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a schematic of gene assembly on a microarray device surfaceor porous matrix. In FIG. 1A, the target gene sequence is dissected intonumber of overlapping oligonucleotides. The 3′ and 5′ are the ends ofthe shown strand. FIG. 1A also shows, relative to the target sequence,primer Pr1; extension product of primer Pr1, which is complementary tooligonucleotide 1; and extension product of complementaryoligonucleotide 1, which is complementary to oligonucleotides 1+2. FIG.1B illustrates one embodiment of the initial steps of an assemblyprocess. In step 1 of assembly, Primer Pr1 is annealed tooligonucleotide 1 and extended by appropriate polymerase enzyme intoproduct complementary to oligonucleotide 1. The second step is melting,re-annealing and extension (i.e., amplification) to lead to productionof larger amount of Pr1 extension product (complementary oligonucleotide1), re-association of the complementary oligonucleotide 1 witholigonucleotide 1, and to annealing of the complementary oligonucleotide1 with oligonucleotide 2 followed by its extension into productcomplementary to oligonucleotides 1+2. FIG. 1C shows a continuation ofthe assembly process from FIG. 1B. Specifically, step 3 of the process(i.e., melting, re-annealing and extension) leads to the same productsas step 2 plus a product complementary to oligonucleotides 1+2+3. Cycles(steps) are repeated until a full-length complementary polynucleotide isformed. The final step is preparation of the final target polynucleotidemolecule in desirable amounts by amplification (i.e., PCR) using twoprimers complementary to the ends of this molecule (PrX and PrY).

FIG. 2 shows a second embodiment of the inventive gene assembly processusing oligonucleotides synthesized in situ onto a microarray device,each having a flanking sequence region containing a restriction enzymecleavage site, followed by a PCR amplification step and followed by aREII restriction enzyme cleavage step.

FIG. 3 shows a schematic for gene assembly using oligos synthesized andthen cleaved from a microarray device. Specifically, in the upper panelmarked “A”, oligonucleotide sequences are connected to the microarraydevice through a cleavable linker (CL) moiety. An example of a cleavablelinker moiety is provided in FIG. 3A. The cleavable linkers aremolecules that can withstand the oligonucleotide synthesis process(i.e., phosphoramidite chemistry) and then can be cleaved to releaseoligonucleotide fragments. Chemical cleavage at cleavable linker CLrecreates usual 3′ end of specific oligos 1 through N. Theseoligonucleotides are released into a mixture. The mixture ofoligonucleotides is subsequently assembled into full-lengthpolynucleotide molecules. In the lower panel marked “B” of FIG. 3,oligonucleotide sequences are connected to the microarray device throughadditional flanking sequence containing a restriction enzyme (RE)sequence site. Another oligonucleotide sequence, complementary to theflanking sequence region, is hybridized to the oligonucleotides on themicroarray device. This recreates a “ds” or double-strandedoligonucleotide structure, each having a RE sequence recognition regionin the flanking sequence region. Digestion of this ds oligonucleotideswith the corresponding RE enzymes at the RE recognition sites in theflanking sequence regions releases the specific oligonucleotides 1through N. When assembled, oligonucleotide sequences 1 through N form afull-length polynucleotide molecule. FIG. 3C: Cleavable linker foroligonucleotide synthesis.

FIG. 4 shows the assembly of a polynucleotide from three oligonucleotidefragments wherein each oligonucleotide fragment was synthesized in situon a microarray device. The fully assembled polynucleotide was 172 mersin length, a length not practically achievable by in situ synthesis. Thefirst embodiment inventive process was used in this example.

FIG. 5 shows the oligonucleotide sequences used to assemble the 172-merpolynucleotide of FIG. 4. The sequences of primers X and Z areunderlined. The Hpa II restriction site is indicated by italicunderlined letters.

FIG. 6 shows a scheme for preparing the sequences of flanking regionsand primers used for preparation of specific oligonucleotide forassembly using the REII enzyme MlyI. Primer 1 is complementary to theoligonucleotide strand on a microarray device and contains a Biotin-TEG(triethylene glycol) moiety. Primer 2 is the same strand as theoligonucleotide strand on microarray device and contains Biotin-TEGmoiety. Any sequence between the primers can be used and is justdesignated by a string of N's.

FIG. 7 shows the results of PCR and Mly I digestion of anoligonucleotide sequence as described in FIG. 6. The clean bands showthe ability to obtain pure oligonucleotides using the second embodimentof the inventive process to cleave off oligonucleotide sequences usingappropriate restriction enzymes.

FIG. 8 shows the sequences from nine oligonucleotides fragments(consecutively numbered 1-9) used to assemble a 290 bp polynucleotide.The flanking regions are shown in bold and underlined. The process usedfor polynucleotide assembly was the second embodiment. The overlappingregions further contained a cleavable site as the Mly I recognition sitefor the Mly I class II restriction endonuclease.

FIG. 9 shows a schematic in the top panel for assembling apolynucleotide from nine oligonucleotides. Nine oligonucleotidesequences, shown in FIG. 8, were amplified by PCR using primers 1 and 2(as described in FIG. 6) into ds DNA fragments containing the sameflanking regions and specific overlapping sequences, digested with Mly Ienzyme to remove flanking sequences, and used for assembly of 290 bp DNAfragment. The columns in the gel shown are M—markers, 1—negativecontrol, assembly without primers FP1 and FP2, 2—negative control,assembly without specific oligos, 3—assembly of 290 bp fragment fromspecific oligos plus amplification with FP1 and FP2 primers. The band incolumn 3 shows a high efficiency of the inventive polynucleotideassembly process.

FIG. 10 shows a sequence of an assembled polynucleotide in Example 4,broken down into its component oligonucleotides.

DETAILED DESCRIPTION OF THE INVENTION

The present invention describes the preparation of a polynucleotidesequence (also called “gene”) using assembly of overlapping shorteroligonucleotides synthesized or spotted on microarray devices or onsolid surface bead devices. The shorter oligonucleotides includesequence regions having overlapping regions to assist in assembly intothe sequence of the desired polynucleotide. Overlapping regions refer tosequence regions at either a 3′ end or a 5′ end of a firstoligonucleotide sequence that is the same as part of the secondoligonucleotide and has the same direction (relative to 3′ to 5′ or 5′to 3′ direction), and will hybridize to the 5′ end or 3′ end of a secondoligonucleotide sequence or its complementary sequence (secondembodiment), and a second oligonucleotide sequence to a thirdoligonucleotide sequence, and so on. In order to design or develop amicroarray device or bead device to be used for polynucleotide assembly,the polynucleotide sequence is divided (or dissected) into a number ofoverlapping oligonucleotides segments, each with lengths preferably from20 to 1000 bases, and most preferably from 20 to 200 bases (FIG. 1A).The overlap between oligonucleotide segments is 5 or more bases,preferably 15-25 bases to that proper hybridization of first to second,second to third, third to fourth and so on occurs. Theseoligonucleotides (or oligos) are preferably synthesized on a microarraydevice using any available method (i.e., electrochemical in situsynthesis, photolithography in situ synthesis, ink jet printing,spotting, etc.). The direction of synthesis relative to the microarraydevice surface or porous matrix covering a microarray device can be from3′ to 5′ or from 5′ to 3′. Preferably, in situ synthesis is done in the3′ to 5′ direction.

In the first embodiment the inventive gene/polynucleotide assemblyprocess uses oligonucleotides immobilized on a microarray device. Themicroarray device itself or a porous reaction layer with immobilizedoligonucleotides can be used for the inventive gene/polynucleotideassembly process.

With regard to FIG. 1B, the process comprises several repeated steps ofmelting, annealing and extension (FIG. 1B), which can be performed inany thermal cycler instrument. The cycling program is similar to theprograms used for PCR. At the first step of gene/polynucleotideassembly, primer Pr1 is added and anneals to oligonucleotide 1 on themicroarray device and then extends by appropriate polymerase enzyme intoproduct complementary to oligonucleotide 1 (called complementaryoligonucleotide 1). At the second step of the process the productcomplementary to oligonucleotide 1 is melted from oligonucleotide 1,primer Pr1 is annealed again to the oligonucleotide 1 as well as productcomplementary to oligonucleotide 1 is partially re-anneals tooligonucleotide 1 and partially anneals to oligonucleotide 2 due to anoverlapping sequence region between oligonucleotide 1 andoligonucleotide 2. Extension of Pr1 leads to production of an additionalamount of Pr1 extension product (complementary oligonucleotide 1). Theannealing of the complementary oligonucleotide 1 to oligonucleotide 2followed by its extension leads to product complementary tooligonucleotides 1+2 (called complementary oligonucleotides 1+2).Similarly, at step 3 of the process melting, re-annealing and extensionlead to the same products as at step 2 plus a product complementary tooligonucleotides 1+2+3. These cycles of melting, annealing and extensionare repeated until full-length polynucleotide is formed. The number ofcycles should be equal or more than the number of oligos on microarraydevice. After formation, the final target polynucleotide molecule isamplified by a PCR process with two primers complementary to the ends ofthis molecule to the desirable amounts.

In a second embodiment, a plurality of oligonucleotides that togethercomprise (with overlapping regions) the target polynucleotide sequenceare synthesized on a microarray device (or can be synthesized on beadsas a solid substrate), wherein each oligonucleotide sequence furthercomprises flanking short sequence regions, wherein each flankingsequence region comprises one or a plurality of sequence sites forrestriction endonuclease, preferably endonuclease class II (ERII)enzymes. Each oligonucleotide is amplified by PCR using appropriateoligonucleotide primers to the flanking sequence regions to form apreparation of a plurality of oligonucleotides. The preparation ofoligonucleotides is treated then with appropriate REII enzyme(s)(specific to the restriction sequences in the flanking sequence regions)to produce flanking fragments and overlapping oligonucleotides that,together comprise the desired polynucleotide sequence. Flankingfragments and PCR primers are removed from the mixture, if desired, bydifferent methods based on size or specific labeling of the PCR primers.The oligonucleotides resembling the desired target polynucleotide thenassembled into the final target polynucleotide molecule using repetitionof the primer extension method and PCR amplification of the finalmolecule.

Specifically, in the second embodiment, the assembly process initiallyuses oligonucleotides immobilized on a microarray device or beads, viaimmobilization techniques, such as spotting or ink jet printing or bydirect in situ synthesis of the microarray device using varioustechniques, such as photolithography or electrochemical synthesis. Theoverlapping oligonucleotide sequences are designed having an overlappingregion and one or two flanking sequence regions comprising a restrictionclass II recognition site (FIG. 2A). The assembled oligonucleotidestogether comprise the target polynucleotide sequence.

The length of flanking sequences is at least the length of REIIrecognition site. The flanking sequences are designed to have minimalhomology to the specific oligonucleotide sequences regions on themicroarray device. The flanking sequences can be the same for eacholigonucleotide fragment, or be two or more different sequences. Forexample, a pair of appropriate primers, called Pr1 and Pr2, was designedto amplify each oligonucleotide on a microarray device (FIG. 2) by PCR.Each primer may contain a binding moiety, such as biotin, that does notaffect their ability to serve as primers. After PCR amplification theamplified ds copy of each oligonucleotide was present in the reactionmixture. This reaction mixture was treated with the appropriate REIIenzyme or enzymes specific for the restriction sites in the flankingsequence regions. The digestion sites for REII were designed, aftercleavage, to produce the desired specific oligonucleotide sequencefragments that, when assembled will form the target polynucleotidesequence. As a result of digestion a mixture of specific double stranded(ds) overlapping oligonucleotide sequence fragments resembling thestructure of desired target polynucleotide, and ds flanking sequenceswere formed. If desired, these flanking sequences and residual primersare removed from the mixture using specific absorption through specificmoieties introduced in the primers (such as, for example, by absorptionon avidin beads for biotin-labeled primers), or based on the sizedifference of the specific oligos and flanking sequences and primers.The mixture of specific oligonucleotide sequences resembling target genesequence is used to assemble the final target polynucleotide moleculeusing repeated cycles of melting, self-annealing and polymeraseextension followed by PCR amplification of the final targetpolynucleotide molecule with appropriate PCR primers designed toamplify. This final PCR amplification step is routinely done in the artand described in, for example, Mullis et al., Cold Spring Harb. Symp.Quant. Biol. 51 Pt 1:263-73, 1986; and Saiki et al., Science 239:487-91,1988. PCR amplification steps generally follow manufacturer'sinstructions. Briefly, A process for amplifying any target nucleic acidsequence contained in a nucleic acid or mixture thereof comprisestreating separate complementary strands of the nucleic acid with a molarexcess of two oligonucleotide primers and extending the primers with athermostable enzyme to form complementary primer extension productswhich act as templates for synthesizing the desired nucleic acidsequence. The amplified sequence can be readily detected. The steps ofthe reaction can be repeated as often as desired and involve temperaturecycling to effect hybridization, promotion of activity of the enzyme,and denaturation of the hybrids formed.

In another embodiment for the assembly step, oligonucleotide sequencesthat together comprise the target polynucleotide molecule are assembledusing a ligase chain reaction as described in Au et al., Biochem.Biophys. Res. Commun. 248:200-3, 1998. Briefly, short oligonucleotidesare joined through ligase chain reaction (LCR) in high stringencyconditions to make “unit fragments” (Fifty microliters of reactionmixture contained 2.2 mM of each oligo, 8 units Pfu DNA ligase(Stratagene La Jolla, Calif.) and reaction buffer provided with theenzyme. LCR was conducted as follows: 95° C. 1 min; 55° C. 1.5 min, 70°C. 1.5 min, 95° C. 30 sec for 15 cycles; 55° C. 2 min; 70° C. 2 min,which are then fused to form a full-length gene sequence by polymerasechain reaction.

In another embodiment the ds oligonucleotide sequences are assembledafter preparation by chain ligation cloning as described in Pachuk etal., Gene 243:19-25, 2000; and U.S. Pat. No. 6,143,527 (the disclosureof which is incorporated by reference herein). Briefly, chain reactioncloning allows ligation of double-stranded DNA molecules by DNA ligasesand bridging oligonucleotides. Double-stranded nucleic acid moleculesare denatured into single-stranded molecules. The ends of the moleculesare brought together by hybridization to a template. The templateensures that the two single-stranded nucleic acid molecules are alignedcorrectly. DNA ligase joins the two nucleic acid molecules into asingle, larger, composite nucleic acid molecule. The nucleic acidmolecules are subsequently denatured so that the composite moleculeformed by the ligated nucleic acid molecules and the template cease tohybridize to each. Each composite molecule then serves as a template fororienting unligated, single-stranded nucleic acid molecules. Afterseveral cycles, composite nucleic acid molecules are generated fromsmaller nucleic acid molecules. A number of applications are disclosedfor chain reaction cloning including site-specific ligation of DNAfragments generated by restriction enzyme digestion, DNAse digestion,chemical cleavage, enzymatic or chemical synthesis, and PCRamplification.

With regard to the second embodiment of the inventive process(illustrated in FIG. 2), a target polynucleotide gene sequence (eitherstrand) is divided into number of overlapping oligonucleotide sequencesby hand or with a software program, as shown in FIG. 1. Theseoligonucleotide sequences, plus flanking sequences A and B (having oneor a plurality of restriction enzyme sites in the flanking regionsequence), are synthesized (in situ) on microarray device, or on a beadsolid surface using standard in situ synthesis techniques, or spotted(pre-synthesized) onto a microarray device using standardoligonucleotide synthesis procedures with standard spotting (e.g.,computer-aided or ink jet printing) techniques. The oligonucleotidesequences are amplified, preferably using a PCR process with a pair ofprimers (Pr1 and Pr2). The primers are optionally labeled with specificbinding moieties, such as biotin. The resulting amplified mixture ofdifferent amplified oligonucleotide sequences are double stranded (ds).The mixture of ds oligonucleotide sequences are treated with anappropriate restriction enzyme, such as an REII restriction enzyme(e.g., Mly I enzyme), to produce mixture of different double stranded(ds) overlapping oligonucleotide sequences that can be assembled intothe structure of the desired polynucleotide (gene) and ds flankingsequences. Optionally, the flanking sequences and residual primers areremoved from the ds oligonucleotide sequence mixture, preferably by aprocess of specific absorption using specific binding moietiesintroduced in the primers (e.g., biotin), or by a process of sizefractionation based on the size differences of the specificoligonucleotide sequences and flanking sequences. The mixture ofspecific oligonucleotide sequences is assembled, for example, by aprocess of repeated cycles of melting, self-annealing and polymeraseextension followed by PCR amplification of the final molecule withappropriate PCR primers designed to amplify this complete molecule(e.g., as described in Mullis et al., Cold Spring Harb. Symp. Quant.Biol. 51 Pt 1:263-73, 1986; and Saiki et al., Science 239:487-91, 1988).

In yet another embodiment of the inventive process (illustrated in FIG.3), the oligonucleotide sequences comprising the target polynucleotidesequence are synthesized on a microarray device or bead solid support,each oligonucleotide having a cleavable linker moiety synthesized withinthe sequence, such that after synthesis, oligonucleotides can be cleavedfrom the microarray device into a solution. Examples of appropriatecleavable linker moieties are shown in FIG. 3A. In addition to thismethod of cleavage, a sequence containing RE enzyme site can besynthesized at the ends of oligonucleotides attached to the microarraydevice. These oligonucleotides on the microarray device then hybridizewith an oligonucleotide complementary to this additional flankingsequence and treated with an RE enzyme specific for the RE enzyme site.This process releases oligonucleotide fragments resembling the structureof the target polynucleotide. This set of oligonucleotides then can beassembled into the final polynucleotide molecule using any one of themethods or combination of the methods of ligation, primer extension andPCR.

In a third embodiment of the inventive process, a plurality ofoligonucleotides that can be assembled into a full length polynucleotideare synthesized on a microarray device (or beads having a solid surface)having specific cleavable linker moieties (FIG. 3A) or capable of beingcleaved from the solid support of the microarray device or beads by achemical treatment. The net effect is to recreate the functional 3′ endsand 5′ ends of each specific oligonucleotide sequence. After treatmentto cleave them, the oligonucleotides (each having overlapping regions)are released into a mixture and used for full-length polynucleotide geneassembly using any of the gene assembly processes described herein.

Specifically, in the third embodiment and as illustrated in FIG. 3, atarget polynucleotide sequence is dissected into number of overlappingoligonucleotide sequences by a software program or on paper, but notnecessarily physically in a laboratory. These oligonucleotide sequencesare physically synthesized on a microarray device. In alternative A, theoligonucleotide sequences are connected to the microarray device throughcleavable linker moiety. Chemical cleavage under basic conditions (e.g.,through addition of ammonia), at cleavable linker CL recreates the usual3′ end of the specific oligonucleotide sequences 1 through N.Oligonucleotide sequences 1 through N are released into a mixture. Themixture of oligonucleotide sequences is used for polynucleotideassembly.

In alternative B, oligonucleotide sequences are connected to amicroarray device through additional flanking sequence regionscontaining a restriction enzyme (RE) sequence site. A secondoligonucleotide fragment, complementary to the flanking sequence, ishybridized to the oligonucleotides on the microarray device. Thisrecreates a ds structure at the flanking sequence region, including theRE recognition site. Digestion of this ds DNA structure with RE enzymespecific to the RE recognition site in the flanking sequence region willrelease specific oligonucleotides 1 through N into a mixture solution.The oligonucleotides 1 through N are able to assemble into apolynucleotide molecule in solution.

In another example of alternative B, oligonucleotides that togetherassemble into the polynucleotide are synthesized on a microarray device,each having a flanking sequence on the microarray side. The flankingsequence further comprises a restriction endonuclease (RE) recognitionsite (see FIG. 3B). Oligonucleotides complementary to the flankingsequence region are added and hybridized to the oligonucleotides onmicroarray device. After hybridization a RE (restriction enzyme specificto the RE sequence in the flanking region) is added to the microarraydevice. Specific oligonucleotide sequences are released from themicroarray device as a result of RE digestion into a mixture. Themixture of specific oligonucleotide sequences ARE assembled into thefull-length polynucleotide sequence.

Example 1

This example illustrates assembly of 172-mer polynucleotide sequencefrom non-cleavable oligonucleotide sequences synthesized on a microarraydevice according to the first embodiment inventive process (FIGS. 4 and5). Three oligonucleotides (sequences shown in FIG. 5) were synthesizedin situ on a microarray device according to an electrochemical process(see U.S. Pat. No. 6,093,302, the disclosure of which is incorporated byreference herein). The oligonucleotide sequences synthesized wereamplified by a PCR reaction with primers X (complementary to the strandof oligo#1) and Z (same strand as Oligo#3) (FIG. 5). After 45 cycles ofPCR using a PCR kit with AmplyGold® enzyme (Applied Biosystems) acorrect DNA fragment of 172 bp was synthesized (FIG. 4). Its subsequentdigestion confirmed the specificity of this enzyme with Hpa II producingtwo fragments of 106 bp and 68 bp.

Example 2

This example illustrates the second embodiment of the inventive processfor preparing oligonucleotides for assembly into full-lengthpolynucleotides by PCR and REII (restriction enzyme) digestion. A singleoligonucleotide sequence was synthesized on a microarray deviceaccording to the procedure in Example 1 (see FIGS. 2 and 6). Theoligonucleotide sequence further comprised 2 flanking sequences, eachhaving a recognition site for a Mly I restriction enzyme. Thismicroarray device was subject to a PCR (25 cycles) reaction with twoprimers (shown in FIG. 7) to produce an amplified PCR fragment mixture.The amplified PCR fragment obtained was digested by Mly I restrictionenzyme and purified by a PCR purification kit (Qiagen) to producespecific oligonucleotides ready for assembly (FIG. 7). Similarly, thisspecific oligonucleotide was purified from the flanking sequences byabsorption of the digestion mixture by Streptavidin-agarose (Sigma).

Example 3

This example illustrates the assembly of a 290 bp polynucleotidesequence from 9 oligonucleotide sequences, each having flankingsequences containing a MlyI restriction site. Each of the nine differentoligonucleotide sequences was synthesized on a microarray device throughan in situ electrochemistry process as described in example 1 herein.

The microarray device containing the nine specific oligonucleotidesequences (with flanking sequences as shown in FIG. 8) was used for PCRamplification of each oligonucleotide sequence using two primers, Primer1 and 2, described in FIG. 6 to form a mixture of ds oligonucleotidesequences. The primers were complementary to the flanking sequences. Themixture of the amplified ds oligonucleotide sequences was digested byMly I enzyme. Specific ds oligonucleotide sequences were purified andthen assembled into the final 290 bp polynucleotide sequence in twosteps as described in FIG. 2 and shown schematically in FIG. 9. At thefirst step of assembly 20 cycles of melting-annealing-extension wereused. The final product was amplified using two primers FP1 and FP2(FIG. 9) in 25 cycles of PCR into a 290 bp polynucleotide DNA.

Example 4

This example illustrates the creation of a cDNA polynucleotide sequencecapable of coding on expression for fusion protein MIP-GFP-FLAG(Macrophage Inflammation Protein—Green Fluorescence Protein—FLAGpeptide) using thirty-eight overlapping oligonucleotide sequences (FIG.10). The 38 oligonucleotides were synthesized on a microarray deviceusing an electrochemical in situ synthesis approach, as described inexample 1. Each oligonucleotide sequence contained a cleavable linkermoiety (see FIG. 3A) at their 3′ end. After simultaneous deprotectionand cleavage of these oligonucleotide sequences by concentrated ammonia,the mixture of oligonucleotide sequences was purified by gel-filtrationthrough the spin column. The purified oligonucleotide sequences wereassembled into a polynucleotide by a process shown schematically in FIG.3. The resulting DNA polynucleotide was 965 bp and contained both a T7RNA-polymerase promoter and a coding sequence for MIP-GFP-FLAG fusionprotein. The polynucleotide assembled in this example was used in astandard transcription/translation reaction and produced the appropriateMIP-GFP-FLAG fusion protein. The translated protein was purified fromthe reaction mixture using anti-FLAG resin (Sigma). The functionalprotein possessed green fluorescence signal in appropriate blue light.Accordingly, this experiment demonstrated that the inventive geneassembly process provided the correct DNA sequence coding for thefunctional protein.

1. A process for creating a mixture of oligonucleotide sequences insolution comprising: (a) synthesizing in situ or spotting a plurality ofoligonucleotide sequences on a microarray device or bead device eachhaving a solid or porous surface, wherein the plurality ofoligonucleotide sequences are attached to the solid or porous surfaceand wherein each oligonucleotide sequence comprises a fragment of atarget polynucleotide sequence; (b) amplifying each oligonucleotidesequence to form a plurality of double stranded oligonucleotidesequences using primers complementary to a primer region of flankingsequences located at the 3′ end and the 5′ end of each fragment, whereineach flanking sequence is from about 7 to about 50 bases and comprisesthe primer region and a sequence segment having a restriction enzymecleavable site; and (c) cleaving the primer regions from the pluralityof double stranded oligonucleotide sequences at the restriction enzymecleavable sites, thereby to produce a plurality of fragments of thetarget polynucleotide sequence, wherein the plurality of fragmentstogether comprise the target polynucleotide sequence.
 2. The process forcreating a mixture of oligonucleotide sequences in solution of claim 1,wherein the flanking sequence is from about 10 to about 20 bases inlength.
 3. The process for creating a mixture of oligonucleotidesequences in solution of claim 1 wherein the restriction enzymecleavable site is a class II endonuclease restriction site sequencecapable of being cleaved by its corresponding class II restrictionendonuclease enzyme.
 4. The process for creating a mixture ofoligonucleotide sequences in solution of claim 3, wherein therestriction endonuclease class II site corresponds to the restrictionsite for a restriction endonuclease class II enzyme selected from thegroup consisting of Mly I, BspM I, Bae I, BsaX I, Bsr I, Bmr I, Btr I,Bts I, Fok I, and combinations thereof.
 5. The process for creating amixture of oligonucleotide sequences in solution of claim 1, wherein theflanking sequences further comprise a binding moiety used to purifycleaved oligonucleotides from flanking sequences.
 6. The process forcreating a mixture of oligonucleotide sequences in solution of claim 1,wherein the process further comprises the step of labeling the flankingsequences during the amplification step (b) using primer sequenceslabeled with binding moieties.
 7. The process for creating a mixture ofoligonucleotide sequences in solution of claim 6, wherein the bindingmoiety is biotin, or fluorescein.
 8. A process for creating a mixture ofoligonucleotide sequences in solution comprising: (a) providing aplurality of oligonucleotides sequences bound on a solid surface,wherein each oligonucleotide sequence comprises a fragment of a targetpolynucleotide sequence; (b) amplifying each oligonucleotide sequence toform a plurality of double stranded oligonucleotide sequences usingprimers complementary to a pair of primer regions of flanking sequenceslocated at the 3′ end and at the 5′ end of each fragment, wherein eachflanking sequence comprises one of the pair of primer regions and asequence segment having a restriction enzyme cleavable site, and whereinthe plurality of oligonucleotides has two or more different flankingregion sequences; and (c) cleaving the primer regions from the pluralityof double stranded oligonucleotide sequences at the restriction enzymecleavable sites, thereby to produce a plurality of fragments, whereinthe plurality of fragments together comprise the target polynucleotidesequence.
 9. The process for creating a mixture of oligonucleotidesequences in solution of claim 8, wherein each double strandedoligonucleotide sequence has an overlapping region corresponding to anext oligonucleotide sequence within the polynucleotide sequence. 10.The process for creating a mixture of oligonucleotide sequences insolution of claim 1, wherein the flanking sequence regions for eacholigonucleotide are the same.
 11. The process for creating a mixture ofoligonucleotide sequences in solution of claim 1, wherein the pluralityof oligonucleotide sequences has two or more different flanking regionsequences.
 12. The process for creating a mixture of oligonucleotidesequences in solution of claim 1, wherein the flanking sequences aredesigned to have minimal homology to the oligonucleotide sequences. 13.The process for creating a mixture of oligonucleotide sequences insolution of claim 1, wherein each flanking sequence has a plurality ofrestriction enzyme cleavable sites.
 14. The process for creating amixture of oligonucleotide sequences in solution of claim 13, wherein atleast one restriction enzyme cleavable site is a class II endonucleaserestriction sequence capable of being cleaved by its corresponding classII restriction endonuclease enzyme.
 15. The process for creating amixture of oligonucleotide sequences in solution of claim 1, furthercomprising purifying the cleaved double stranded oligonucleotidesequences by size fractionation.
 16. The process for creating a mixtureof oligonucleotide sequences in solution of claim 8, wherein therestriction enzyme cleavable site is a class II endonuclease restrictionsite sequence capable of being cleaved by its corresponding class IIrestriction endonuclease enzyme.
 17. The process for creating a mixtureof oligonucleotide sequences in solution of claim 16, wherein therestriction endonuclease class II site corresponds to the restrictionsite for a restriction endonuclease class II enzyme selected from thegroup consisting of Mly I, BspM I, Bae I, BsaX I, Bsr I, Bmr I, Btr I,Bts I, Fok I, and combinations thereof.
 18. The process for creating amixture of oligonucleotide sequences in solution of claim 8 wherein eachflanking sequence has a plurality of restriction enzyme cleavable sites.19. The process for creating a mixture of oligonucleotide sequences insolution of claim 18, wherein at least one restriction enzyme cleavablesite is a class II endonuclease restriction sequence capable of beingcleaved by its corresponding class II restriction endonuclease enzyme.20. A process for creating a mixture of oligonucleotide sequences insolution comprising: providing a plurality of oligonucleotidessequences, wherein each oligonucleotide sequence comprises a fragment ofa target polynucleotide sequence and further comprises two flankingsequences, one at the 3′ end and the other at the 5′ end of eachfragment, wherein each flanking sequence comprises a primer region and asequence segment having a restriction enzyme cleavable site; amplifyingeach oligonucleotide sequence using primers complementary to a pair ofprimer regions of the flanking sequences to form a plurality of doublestranded oligonucleotide sequences; and cleaving the primer regions fromthe plurality of double stranded oligonucleotide sequences at therestriction enzyme cleavable sites, thereby to produce a plurality offragments, wherein the plurality of fragments together comprise thetarget polynucleotide sequence.
 21. The process for creating a mixtureof oligonucleotide sequences in solution of claim 20, wherein theplurality of oligonucleotide sequences has two or more differentflanking region sequences.
 22. The process for creating a mixture ofoligonucleotide sequences in solution of claim 20, wherein the flankingsequence regions for each oligonucleotide are the same.
 23. A processfor creating a mixture of oligonucleotide sequences in solution, theprocess comprising providing a plurality of oligonucleotides sequences,wherein each oligonucleotide sequence comprises a fragment of a targetpolynucleotide sequence and the fragments together comprising the targetpolynucleotide sequence and wherein each oligonucleotide furthercomprises at least one flanking sequence at the 3′ end, the 5′ end, orat the 3′ end and the 5′ end of each fragment, wherein each flankingsequence comprises a primer binding site, each primer biding regionbeing complementary to a primer permitting amplification of theplurality of oligonucleotides.
 24. The process of claim 23, wherein eachflanking sequence further comprises a sequence segment permittingremoval of the primer binding sites.
 25. The process of claim 24,wherein the sequence segment permitting removal of the primer bindingsite is a class II endonuclease restriction site sequence capable ofbeing cleaved by its corresponding class II restriction endonucleaseenzyme.
 26. The process of claim 23, wherein each oligonucleotidefurther comprises a cleavable linker moiety.
 27. The process of claim23, wherein the flanking sequence regions are designed to have minimalhomology to the oligonucleotide sequences.
 28. The process of claim 23,wherein each oligonucleotide has a sequence region that is the same asor complementary to the sequence region of the next oligonucleotide. 29.The process of claim 23, wherein the plurality of oligonucleotides areprovided bound on a solid or porous surface.
 30. A composition forassembly of a target polynucleotide sequence, the composition comprisinga plurality of different oligonucleotides sequences, wherein eacholigonucleotide sequence comprises a fragment of a target polynucleotidesequence and the fragments together comprising the target polynucleotidesequence, wherein each oligonucleotide further comprises at least oneflanking sequence at the 3′ end, the 5′ end, or at the 3′ end and the 5′end of each fragment, and wherein each flanking sequence comprises aprimer binding site.
 32. The composition of claim 30, further comprisingat least one primer complementary to the primer binding site of the atleast one flanking sequence and permitting amplification of theplurality of different oligonucleotides.
 33. The composition of claim30, wherein each flanking sequence further comprises a sequence segmentpermitting removal of the primer binding sites.
 34. The composition ofclaim 33, wherein the sequence segment permitting removal of the primerbinding site is a restriction enzyme cleavable site.
 35. The compositionof claim 34, wherein the restriction enzyme cleavable site is a class IIendonuclease restriction site sequence capable of being cleaved by itscorresponding class II restriction endonuclease enzyme.
 36. Thecomposition of claim 30, wherein the flanking sequence regions for theplurality of different oligonucleotides are the same.
 37. Thecomposition of claim 30, wherein the flanking sequence regions for theplurality of different oligonucleotides are two or more differentflanking sequence regions.
 38. The composition of claim 30, wherein eacholigonucleotide has a sequence region that is the same as orcomplementary to the sequence region of another oligonucleotide.
 39. Thecomposition of claim 30, wherein the plurality of differentoligonucleotides are provided bound on a solid or porous surface.
 39. Asolid or porous surface comprising a plurality of cleavableoligonucleotides sequences immobilized thereon, wherein eacholigonucleotide sequence has an overlapping sequence corresponding to anext oligonucleotide of the composition, wherein the plurality ofoverlapping sequences of the composition together comprise thepolynucleotide sequence and wherein each oligonucleotide furthercomprises at least one flanking sequence at the 3′ end, the 5′ end, orat the 3′ end and 5′ end of each overlapping sequence, wherein eachflanking sequence comprises a primer binding site, each primer bidingsite being complementary to a primer permitting amplification of theplurality of oligonucleotides.
 40. The composition of claim 39 whereineach oligonucleotide comprises a cleavable linker moiety.
 41. Thecomposition of claim 39 wherein each oligonucleotide further comprises asequence segment permitting removal of the primer binding sites.
 42. Thecomposition of claim 41 wherein the sequence segment has a restrictionenzyme cleavable site is capable of being cleaved by a type IIrestriction endonuclease.
 43. The composition of claim 39 wherein theflanking sequence regions are the same.
 44. The composition of claim 39wherein the flanking sequence regions are designed to have minimalhomology to the oligonucleotide sequences.
 45. The composition of claim39 wherein each oligonucleotide has a sequence region that is the sameas or complementary to the sequence region of the next oligonucleotide.